Evidence map›Paper›PMID 34989133›Full record

ArticleThoracic cancer2022

Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.

Yusuke Murakami, Akihiro Tamiya, Yoshihiko Taniguchi, Yuichi Adachi, Takatoshi Enomoto, Koji Azuma, Yuji Inagaki, Shunichi Kouno, Yoshinobu Matsuda, Kyoichi Okishio and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yusuke MurakamiDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Akihiro TamiyaDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.ORCID 0000-0003-3599-2583
Yoshihiko TaniguchiDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Yuichi AdachiDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Takatoshi EnomotoDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Koji AzumaDepartment of Respiratory Medicine, Kinki Central Hospital, Itami, Japan.
Yuji InagakiDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Shunichi KounoDepartment of Respiratory Medicine, Fujioka General Hospital, Fujioka, Japan.
Yoshinobu MatsudaDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Kyoichi OkishioClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
Shinji AtagiClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
NHO Kinki Chuo Chest Medical Center · JPOsaka City University · JPFujieda Municipal General Hospital · JPKinki Central Hospital · JPNaga Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNivolumab, an immune checkpoint inhibitor (ICI), has changed the treatment paradigm for advanced non-small cell lung cancer (NSCLC). However, factors associated with long-term survival in NSCLC patients treated with ICIs remain unknown. This study aimed to evaluate patient characteristics and clinical laboratory changes related to long-term survival in NSCLC patients treated with nivolumab, using real-world data.

methodsWe retrospectively reviewed the medical records of consecutive patients with advanced NSCLC with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 treated with nivolumab. We defined patients with overall survival (OS) ≥3 years as long-term survivors. We evaluated the differences in patient characteristics and tumor response between nonlong-term survivors and long-term survivors and performed univariate and multivariate analyses of factors associated with long-term survival.

resultsOut of 213 patients with advanced NSCLC treated with nivolumab, 162 patients with ECOG-PS ≤1 were included in the study. Young age, ECOG-PS 0, absolute neutrophil count decrease, lymphocyte percentage increase, and neutrophil-to-lymphocyte ratio (NLR) change (ΔNLR) <1 were significantly associated with long-term survival. Long-term survivors had significantly higher response and disease control rates than nonlong-term survivors. Multivariate analysis showed that ΔNLR <1 was significantly associated with long-term survival. Further, OS was significantly different between the PS 0 and PS 1 groups (median OS: 32.0 months vs. 10.6 months) and the nonincreasing NLR and increasing NLR groups (median OS: 20.8 months vs. 5.7 months).

conclusionsΔNLR <1 was a significant long-term survival factor compared to ΔNLR ≥1 in advanced NSCLC patients treated with nivolumab.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNivolumabPrognosisRetrospective StudiesNivolumablong-term survivorsneutrophil-to-lymphocyte rationivolumabnon-small cell lung canceroverall survival

Identifiers

PMID34989133
PMCPMC8841702
OpenAlexW4205810692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.